Weight-Loss Jabs, Muscle Loss, and Why Strength Training Matters More Than Ever

Weight-loss injections like Ozempic, Wegovy, and Mounjaro are everywhere right now. They’re being talked about in the news, on podcasts, in clinics, and in everyday conversations.

And for good reason: these medications can be highly effective for reducing body weight.

But there’s an important part of the conversation that often gets missed:

When body weight drops quickly, not all of that loss is body fat. A lot of it comes from lean mass (muscle) — and that makes resistance training more important than ever.

Why Resistance Training Matters More Than Ever If You’re Using Weight-Loss Jabs

Weight loss medications have shown to produce substantial weight loss.

That said, the goal is not simply to become lighter.

The real goal is to become healthier, stronger, and more capable.

And that is where strength training becomes essential.

1. Weight loss is not the same thing as fat loss

Recent reviews on GLP-1–based medications note that, while a large share of the weight lost is fat mass, lean mass can also fall dramatically. A 2024 review of changes in lean body mass with GLP-1 receptor agonists reported that some studies found lean-mass reductions ranging from 40% to 60% of total weight lost, while others reported lower proportions. The overall message is that body-composition outcomes vary, but preserving muscle should be an active priority.

A 2025 SURMOUNT-1 body-composition substudy on tirzepatide found that about 75% of the weight lost was fat mass and about 25% was lean mass. That is better than many people fear, but it still means lean tissue can be lost during aggressive weight reduction.

2. Muscle is what helps you look, feel, and function better

Muscle is not just about appearance. It supports strength, posture, daily function, metabolic health, and long-term independence.

Resistance training is the best ways to increase or preserve lean mass. A meta-analysis found that resistance training alone was the most effective exercise mode for increasing lean mass compared with no-exercise controls.

That matters because if someone loses scale weight but also loses too much muscle, they may end up smaller, but not necessarily stronger, fitter, or healthier in the ways that matter most day to day. This is an inference from the body-composition and resistance-training evidence.

3. Bone health matters too

One of the most useful recent studies here was a 2024 randomized clinical trial published in JAMA Network Open. After initial diet-induced weight loss, people were assigned to exercise alone, liraglutide alone, combination treatment, or placebo for 52 weeks.

The key finding: the combination of exercise plus GLP-1 medication was the most effective strategy while preserving bone health. Liraglutide alone reduced hip and spine bone mineral density more than exercise alone, despite similar weight loss. Exercise alone also increased lean mass while preserving hip and spine bone density.

That is a strong reason not to treat these medications as a “take the jab and do nothing else” solution.

4. If medication stops, the habits still need to be there

Another major issue is what happens when treatment ends.

A post hoc analysis of the SURMOUNT-4 trial published in JAMA Internal Medicine in 2025 found that among participants who stopped tirzepatide after initial weight reduction, most regained 25% or more of their lost weight within a year, and greater regain was associated with greater reversal of cardiometabolic improvements.

Semaglutide withdrawal data have shown a similar pattern: after treatment withdrawal, participants regained a substantial proportion of the lost weight over the following year.

This is why resistance training, movement, and nutrition habits matter so much. Medication can help create the opportunity for change, but training is what helps build a body that keeps more of that progress. That final point is an inference supported by the withdrawal and exercise literature.

5. The best approach is not medication versus training — it’s medication plus training

The best takeaway from the current evidence is not that these medications are “bad.”

It is that they are more effective when paired with exercise, especially resistance training, and likely adequate protein intake as well. Reviews in 2024 and 2025 have emphasised concern around lean-mass loss during GLP-1–based weight reduction and highlighted exercise and nutrition as key strategies to mitigate that risk.

In simple terms:

If fat loss is the goal, medication may help.

If better body composition is the goal, strength training is non-negotiable.

If long-term results are the goal, habits still matter.

Bottom line

Weight-loss jabs can be powerful tools. But they do not replace training.

In fact, the newer these drugs get, the more important resistance training becomes.

Because the real win is not just losing weight.

It is keeping muscle, protecting bone, improving strength, and creating results you can hold onto.

Papers referenced

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.

• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine.2022.

• Neeland IJ et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. 2024.

• Alissou M et al. A systematic review of the effect of semaglutide on lean mass. 2024.

• Look M et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. 2025.

• Jensen SBK et al. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment. JAMA Network Open. 2024.

• Horn DB et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity. JAMA Internal Medicine. 2025.

• Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. 2022.

• Lopez P et al. Resistance training effectiveness on body composition and body weight outcomes in individuals with overweight and obesity across the lifespan. 2022.

• Kokura Y et al. Enhanced protein intake on maintaining muscle mass during weight loss in adults with overweight or obesity. 2024.